Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.45 |
| ▸ | ACE | P12821 | 4/20 | 0.45 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869400 | 1.00 | HDAC1 (0.46) | HDAC1ACE2ACEMMEHDAC3 | |
| SCHEMBL5869448 | 1.00 | HDAC1 (0.46) | HDAC1ACE2ACEMMEHDAC3 | |
| SCHEMBL5869393 | 1.00 | HDAC1 (0.46) | HDAC1ACE2ACEMMEHDAC3 | |
| SCHEMBL5870075 | 1.00 | HDAC1 (0.46) | HDAC1ACE2ACEMMEHDAC3 | |
| SCHEMBL5869464 | 0.89 | ACE2 (0.59) | HDAC1ACE2ACEHDAC3HDAC4 | |
| SCHEMBL5869795 | 0.89 | ACE2 (0.59) | HDAC1ACE2ACEHDAC3HDAC4 | |
| SCHEMBL5869967 | 0.83 | ANPEP (0.45) | HDAC1MME | |
| SCHEMBL5869918 | 0.81 | CASR (0.47) | HDAC1ACE2ACEHDAC3HDAC2 | |
| SCHEMBL1690989 | 0.79 | ACE (0.47) | ACE2ACEMMELTA4H | |
| SCHEMBL5870099 | 0.78 | TRHDE (0.61) | ACE2ACEMMELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | HDAC1 236/4885ACE2 2/4885ACE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.